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Abstract: The cell lines of the NCI-60 panel represent different cancer types and have been 
widely utilized for drug screening and molecular target identification. Screening these cell 
lines for envelope proteins or gene sequences related to xenotropic murine leukemia viruses 
(X-MLVs) revealed that one cell line, EKVX, was a candidate for production of an 
infectious gammaretrovirus. The presence of a retrovirus infectious to human cells was 
confirmed by the cell-free transmission of infection to the human prostate cancer cell line 
LNCaP. Amplification and sequencing of additional proviral sequences from EKVX 
confirmed a high degree of similarity to X-MLV. The cell line EKVX was established 
following passage of the original tumor cells through nude mice, providing a possible source 
of the X-MLV found in the EKVX cells. 
Keywords:  EKVX; NCI-60; human cell line; xenotropic murine leukemia virus; 
gammaretrovirus  
 
1. Introduction 
Continuous cell lines established from human cancer specimens are critical to cancer research. 
Biosafety guidelines have been established for handling these cell lines because of the potential 
presence of infectious agents. The NCI-60 panel comprises cell lines derived from human tumors from 
various organs (Table 1). The panel was developed by the Developmental Therapeutics Program 
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(DTP) of the National Cancer Institute (NCI) as an in vitro drug screening tool [1], and at the time of 
its establishment, all cell lines were tested for known pathogens [2]. The NCI-60 panel is currently 
used to screen up to 3000 synthetic compounds or natural products per year for potential anticancer 
activity and is also frequently used for molecular target identification 
(dtp.nci.nih.gov/branches/btb/ivclsp.html). The DTP has supplied the cell lines of the panel to a large 
number of other research laboratories. Because of their widespread use, the discovery of xenotropic 
murine leukemia virus-related virus (XMRV) prompted us to screen the NCI-60 cell lines for 
previously undetected infectious retroviruses.  
Table 1. Derivation of the cell lines of the NCI-60 panel and results of virus screening. 
Cell line 
name  Tumor type 
Immuno-
blotting 
for Env 
PCR for 
env
a 
PCR for 
gag
a 
Passaged 
through 
mice
b 
Reference
BT-549  Breast  -  -  -  N
c   
Hs-578T  Breast  -  -  -  N  [3] 
MCF-7  Breast  -  -  -  N  [4] 
MDA-MB-231  Breast  -  -  -  N  [5] 
T-47D  Breast  -  -  -  N  [6] 
MDA-MB-468  Breast  -  -  -  N  [7] 
SF-268  CNS  -  -  -  N  [8] 
SF-295  CNS  -  -  -  N  [8] 
SF-539  CNS  -  -  -  N  [9] 
SNB-19
d  CNS  -  -  -  N  [10-12] 
SNB-75  CNS  -  -  -  N  [10,11] 
U251
d  CNS  -  -  -  N  [12,13] 
COLO-205  Colon  -  -  -  N  [14] 
HCC-2998  Colon  -  -  -  Y
e   
HCT-116  Colon  -  -  -  N  [15] 
HCT-15  Colon  -  -  -  N  [16] 
HT29  Colon  -  -  -  N  [17] 
KM12
f  Colon  -  -  -  N  [18] 
SW-620  Colon  -  -  -  N  [19] 
CCRF-CEM  Leukemia  -  -  -  N  [20] 
HL-60  Leukemia  -  -  -  N  [21] 
K562  Leukemia  -  -  -  N  [22] 
MOLT-4  Leukemia  -  -  -  N  [23] 
RPMI-8226  Leukemia  -  -  -  N  [24] 
SR  Leukemia  -  -  -  N  [25] 
LOX IMVI  Melanoma  -  -  -  Y  [26,27] 
M14
g  Melanoma  -  -  -  N  [28,29] 
MALME-3M  Melanoma  -  -  -  N  [17] 
MDA-MB-435
g  Melanoma  -  -  -  N  [7,29-31] 
SK-MEL-2  Melanoma  -  -  -  N  [17] 
SK-MEL-28  Melanoma  -  -  -  N  [32] 
SK-MEL-5  Melanoma  -  -  -  N  [32] Viruses 2011, 3                                       
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UACC-257  Melanoma  -  -  -  N
e   
UACC-62  Melanoma  -  -  -  N
e   
A549 ATCC  Non-Small Cell Lung  -  -  -  N  [33] 
EKVX  Non-Small Cell Lung  +  +  +  Y  [26] 
HOP-62  Non-Small Cell Lung  -  -  -  Y
e  [34,35] 
HOP-92  Non-Small Cell Lung  -  -  -  N
e  [34,35] 
NCI-H226  Non-Small Cell Lung  -  -  -  N  [36,37] 
NCI-H23  Non-Small Cell Lung  -  -  -  N  [36,37] 
NCI-H322M  Non-Small Cell Lung  -  -  -  N  [37-39] 
NCI-H460  Non-Small Cell Lung  -  -  -  N  [36,37] 
NCI-H522  Non-Small Cell Lung  -  -  -  N  [36,37] 
IGR-OV1  Ovarian  -  -  -  N  [40] 
NCI/ADR-
RES
h  Ovarian  -  -  -  N  [41-43] 
OVCAR-3  Ovarian  -  -  -  N  [44] 
OVCAR-4  Ovarian  -  -  -  N  [45] 
OVCAR-5  Ovarian  -  -  -  N  [45] 
OVCAR-8  Ovarian  -  -  -  N  [45,46] 
SK-0V-3  Ovarian  -  -  -  N  [17] 
DU145  Prostate  -  -  -  N  [47] 
PC-3  Prostate  -  -  -  N  [48] 
A498  Renal  -  -  -  N  [33] 
ACHN  Renal  -  -  -  N  [49] 
CAKI-1  Renal  -  -  -  N  [17] 
RXF-393  Renal  -  -  -  Y  [50] 
SN12C  Renal  -  -  -  N  [51] 
TK-10  Renal  -  -  -  N  [52] 
UO-31  Renal  -  -  -  U
i   
786-0  Renal  -  -  -  N  [53] 
a“+”indicates a definitive band of the expected size was observed. 
bY=Yes. N=No. U=Unknown; no information was available from literature references. 
cThis cell line was obtained from ATCC. According to the ATCC description: “The BT-549 line was 
isolated in 1978 by W.G. Coutinho and E. Y. Lasfargues.  Source tissue consisted of a papillary, 
invasive ductal tumor which had metastasized to 3 of 7 regional lymph nodes.” The establishment of 
other breast cancer cell lines by the same group has been described [54]. 
d SNB-19 and U251 are derived from the same individual [12]. 
e Michael Alley, NCI, personal communication. 
f The KM12 cell line is the same as KM12C in Morikawa et al. [18] (Michael Alley, NCI, personal 
communication). 
g Current samples of M14 and MDA-MB-435 are related [29]. MDA-MB-435 was originally isolated 
as a breast cancer cell line. 
h NCI/ADR-RES was originally described as a breast cancer cell line, but is related to the ovarian 
cancer cell line OVCAR-8 [41]. 
i Highly unlikely to have been passaged through mice (W. Marston Linehan, NCI, personal 
communication). 
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XMRV is a type C gammaretrovirus first identified in human prostate tumors [55], although 
considerable controversy surrounds the detection of XMRV in human samples [56,57]. The prostate 
cancer cell line 22Rv1 produces infectious XMRV [58], but other prostate cancer cell lines, e.g., 
DU145 and LNCaP, do not [59]. Hue et al. [60] recently reported that 2.2% of a large number of cell 
lines tested by PCR were positive for xenotropic murine leukemia virus (X-MLV) gag sequence. We 
used immunoblotting and PCR assays capable of detecting XMRV and other X-MLVs to screen the 
NCI-60 panel of tumor cell lines.  
2. Results and Discussion  
2.1. The Lung Cancer Cell Line EKVX Tested Positive by Both Immunoblotting for Viral Envelope 
Protein and by PCR for gag and env Viral Gene Sequences  
Total protein lysates were prepared from all 60 cell lines. Viral envelope protein (Env, also known 
as gp70) was detected by immunoblotting with monoclonal antibody 7C10 [61], which was raised 
against the envelope protein of Friend spleen focus-forming virus and which cross-reacts with XMRV 
and other X-MLV envelope proteins. A positive signal was detected in the lysate of only 1 cell line, 
EKVX (Table 1 and Figure 1A), a lung adenocarcinoma–derived cell line [26]. As a second means of 
screening for virus, PCR for XMRV and X-MLV–related gag and env sequences was performed. In 
concordance with the immunoblotting results, only EKVX yielded prominent bands of the expected 
size with both the env and gag primers, 533 bp and 731 bp, respectively (Table 1 and Figures 1B and 
1C). This result is consistent with Hue et al. [60], who detected MLV-like sequences in EKVX by 
PCR. To rule out the possibility that EKVX cultures or derived materials were contaminated with 
mouse cells or DNA containing endogenous X-MLVs that could give rise to the env and gag products, 
we used nested PCR as described by Ono et al. [62] to test for the presence of mouse mitochondrial 
DNA. Although we could reliably detect 1/10
6 equivalents of mouse genomic DNA spiked into human 
genomic DNA, no mouse mitochondrial PCR products were observed with up to 250 ng of EKVX 
genomic DNA (data not shown). We were also unable to detect mouse DNA contamination using a 
single-round (45 cycles) PCR assay for intracisternal A particles (IAP) [63] on up to 600 ng of EKVX 
genomic DNA (Figure 1D). The mouse IAP products are ~200-300 bp; the ~100 bp band in the HCT-
116 lane may be a primer dimer product, as it was observed frequently in no template controls in 
additional experiments.  
We observed a faint ladder of background bands in all cell lines with the env primers. Therefore, we 
tested a subset of first round env products with nested primers, and a band of the appropriate size was 
only detected with EKVX (data not shown). The first round background bands were not observed in 
two representative cell line DNA samples (HCT-116 and DU145) spiked with a small amount (1/10
6) 
of genomic DNA containing the target DNA sequence (data not shown). Because no mouse DNA was 
detected in HCT-116 or DU145 genomic DNA using the IAP assay (Figure 1D), the background bands 
may have been the result of mispriming on human DNA sequences. A few cell lines gave rise to 
products of incorrect size with the gag primers (e.g., HCT-116 in Figure 1C), but no corresponding 
envelope PCR product was observed, and no product was detected using nested primers for gag (data 
not shown).  Viruses 2011, 3                                       
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Lung can serve as a point of entry for virus infection. A search of the GEO database [64] reveals 
numerous examples of expression of the X-MLV/XMRV receptor XPR1 [65] in human lung cells. 
Although potential contamination with mouse sequences was not ruled out, XMRV sequences were 
reported in human respiratory secretions [66], suggesting that lung could be a target for MLV-like 
viruses. However, all 8 of the other lung cancer cell lines in the NCI-60 panel and 4 additional lung 
cancer cell lines [NCI-H1666, NCI-H650, NCI-H2122, NCI-H358; obtained from M. Lerman, NCI 
(data not shown)] that we tested by immunoblotting were negative for MLV-like virus.  
Figure 1. Detection of viral protein and DNA in the human lung adenocarcinoma cell line 
EKVX. Immunoblotting and PCR were carried out on all 60 cell lines of the panel; a 
subset are shown. Immunoblotting of total protein lysates from lung cancer cell lines for 
Env with monoclonal antibody 7C10 (A). XMRV-infected LNCaP cell lysate 
[LNCaP/XMRV(+)] is included as a positive control. Env is present as both a precursor 
form (upper band) and a processed surface unit (lower band). Immunoblotting with -actin 
antibody was used to confirm equal loading. Single-round PCR of genomic DNA for env 
(B) and gag (C) sequences. Template is genomic DNA from cell lines of the NCI-60 panel. 
Arrowheads indicate the expected fragment sizes: 533 bp for env and 731 bp for gag. 
Negative (no template) controls were run on separate gels and no products of the expected 
size were observed (data not shown). (D) EKVX and other representative cell lines, 
DU145 and HCT-116, were tested for mouse contamination by PCR for IAP using 600 ng 
genomic DNA as template. The positive control is genomic DNA from a mouse cell line 
diluted 1/10
5 in human cell line genomic DNA.  
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Figure 1. Cont. 
 
 
 
2.2. EKVX Produces Virus Capable of Infecting Human Cells  
Cell-free supernatants were prepared from cultures of EKVX cells. Reverse transcriptase activity 
was detected in the EKVX supernatant using manganese, but not magnesium (data not shown), 
indicative of a mammalian type C retrovirus reverse transcriptase [67]. The ability of the EKVX viral 
supernatant to infect and spread in human cells was assessed using the human prostate cancer cell line 
LNCaP. LNCaP cells pretreated with polybrene were incubated with cell-free EKVX supernatant or 
fresh media (negative control). Cells were subcultured and total protein lysates were prepared at 10 
and 16 days post-infection. Analysis by immunoblotting with monoclonal antibody 7C10 and with 
goat anti-Rauscher MLV p30 indicated the presence of capsid and envelope viral proteins in the lysate 
(Figure 2), indicating the establishment and spread of infection from the EKVX supernatant.  Viruses 2011, 3                                       
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Figure 2. Transmission of infection by a cell-free EKVX supernatant. Subconfluent 
LNCaP cells were infected with filtered supernatant from EKVX cells (EKVX) or with cell 
culture medium as a negative control (Mock) in the presence of polybrene. Total protein 
lysates were prepared at 10 and 16 days post-infection (dpi). Lysates were subjected to 
electrophoresis and immunoblotting with monoclonal antibody 7C10 for Env and with goat 
anti-RLV p30 capsid. Immunoblotting with -actin antibody was used to confirm equal 
loading.  
 
2.3. The EKVX Virus Is a Xenotropic Murine Leukemia Virus  
The nucleotide sequences of the gag and env PCR fragments amplified from EKVX genomic DNA 
were determined. Sequences of the EKVX gag and env fragments were more closely related to X-
MLVs than to XMRV (98% vs. 87% identity for gag; 99% vs. 92% identity for env). Based on these 
results, primers were designed to amplify additional regions in the LTR, gag, and env based on the 
sequence of DG-75 X-MLV. The sequences of these PCR products were determined and are aligned 
with representative XMRV and X-MLV sequences in Figure 3. The LTR-gag region of the EKVX 
virus lacks several of the defining characteristics of XMRV while aligning with 99% identity with the 
X-MLV sequence; most notably, it lacks the 14 bp deletion found in U3 and the short additions and 24 
bp deletion found in the gag-leader of XMRV (Figure 3A). The primer binding sites for the EKVX 
sequence and the X-MLV sequence shown in Figure 3A are complementary to Gln-tRNAs, whereas 
that for XMRV is complementary to Pro-tRNA [68]. Gln-tRNA binding sites have been reported for 
numerous endogenous MLVs [69-71]. Also of note within the gag-leader region, MLV sequences 
contain an alternative (CTG) start codon, upstream of the ATG start codon, that yields a glycosylated 
precursor (glyco-Gag) [72]. In contrast to XMRV, which has an in-frame stop codon that precludes Viruses 2011, 3                                       
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glyco-Gag synthesis [55], there is no stop codon between the CTG and ATG gag start codons and they 
are in frame with each other, suggesting that the EKVX virus should produce glyco-Gag. The env 
region (Figure 3B) lacks the trinucleotide G insertion found in XMRV, and the env-LTR region 
(Figure 3C) is missing the same 14 bp deletion in U3 as noted in Figure 3A. Together, these sequence 
data confirm that the EKVX virus is more closely related to X-MLVs than to the reported sequences of 
XMRV.  
Xenotropic MLVs are so named because they can infect non-mouse species but cannot infect most 
laboratory strains of mice. X-MLV sequences are present as endogenous viruses in all laboratory and 
some house mouse strains [73-77], and endogenous viruses can be activated to produce infectious virus 
under certain conditions such as chemical or radiation exposure or immune induction [78-82]. Because 
EKVX was derived by passage through a nude mouse [26], the virus in the cell line may have been 
present in the original tumor or may have been acquired from nude mouse cells producing X-MLV. 
Several instances of human tumors and cell lines passed through nude mice having acquired viruses 
from the host have been reported [83-89]. However, not all cells passaged in mice acquire a virus. 
Indeed, four other cell lines of the NCI-60 panel are known to have been established after passage 
through mice (Table 1), and these tested negative for X-MLVs. The propensity for acquisition of a 
virus may depend on the strain of mouse, the means of immune suppression, the characteristics of the 
xenografted tumor, and whether the experimental protocol includes any additional factors (chemical 
exposure, radiation) that could promote the activation of an endogenous virus. Suzuki et al. [86] found 
that cells from 6/9 tumors transplanted into nude mice produced infectious murine type-C virus. Lusso 
et al. [85] found that cells recovered from all 6 human hematopoietic tumors studied that were 
transplanted into splenectomized, irradiated, and anti-asialo-GM1–treated nude mice acquired X-MLV 
infections. In other studies in which a variety of solid tumors were implanted as xenografts in nude 
mice or mice treated with mouse thymocyte antiserum, only 1/9 [87], 1/12 [84], and 2/11 [88] 
xenografts were associated with type C retroviruses. Intriguingly, Tralka et al. [88] reported IAP 
production in the human osteosarcoma cells that had acquired X-MLV infection. In a recent study, 
Zhang et al. [89] found evidence that 6/23 (mouse DNA-free) human cell lines established following 
passage through mice had been infected with X-MLV. Because of the possibility that the EKVX 
human lung cancer cell line acquired its X-MLV upon passage through nude mice, our study sheds no 
light on the controversy of whether X-MLV infections occur naturally in the human population.   
The identification of a human infectious retrovirus in a commonly handled cell line is of concern on 
multiple counts: 1) unknown risk of infection and health risks to persons exposed to the virus, 2) 
unanticipated influence of infection and expression of viral proteins on experimental results [85,86], 
and 3) risk of spread of infectious virus to other cultured cell lines [89]. Infection of cells with X-MLV 
significantly altered the interactions of HIV-1 with those cells compared to their uninfected 
counterparts [85]. With respect to the potential for unintended spread of the virus among cultures, two 
reported examples of X-MLV in human cell lines that had not been transplanted into mice appear to 
have resulted from vertical transmission of virus from another infected cell line [90,91]. Zhang et al. 
[89] found that non-xenograft cell lines maintained in a xenograft-free facility showed no evidence of 
MLV infection, whereas 17% of non-xenograft cell lines cultured in laboratories that also maintained 
xenograft cultures became infected with MLV. Our study indicates that the X-MLV present in the 
EKVX cell line has not spread to other cell lines of the NCI-60 panel maintained by the DTP.  Viruses 2011, 3                                       
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Figure 3. Nucleotide sequence from the LTR, gag, and env regions of the EKVX virus. 
The sequences of regions of the EKVX virus are aligned with XMRV (VP62; accession 
no. DQ399707) and an endogenous X-MLV provirus from chromosome 13 (Chr13 X-
MLV) of a C57BL/6 mouse (accession no. CT030655, nt 54,685-63,371). U3 sequence 
from the 3 end of XMRV VP62 sequence was appended to the 5 end in the figure to 
generate the predicted provirus sequence. Numbering for XMRV is according to XMRV 
VP62, with nt 1 (at the U3/R transition) highlighted in gray. Numbering for EKVX 
indicates the nucleotide number for each fragment shown. Conserved nucleotides are 
indicated by *. (A) LTR-gag leader region, compiled from PCR fragments generated with 
primers DG-75 7762F/DG-75 287R and DG-75 7945F/DG-75 664R. The primer binding 
site is underlined and shown in blue. The upstream glyco-Gag start is highlighted in green, 
and the in-frame stop codon in XMRV is shown in red. The start codon for the Gag 
polyprotein is highlighted in yellow.  (B) env region, generated with primers VP62 5922F / 
VP62 6454R. (C) env-LTR region, generated with primers DG-75 7607F/DG-75 7968R. 
The stop codon for the Env polyprotein is shown in red.  
A 
 
XMRV            TTGCAAGGCATGGAAAAGTACCAGAGCTGAGTTCTCAAAAGTTACAAGGAAGTTTAATTA 7834 
EKVX            TTGCAAGGCATGAAAAAGTACCAGAGCTGAGTTCTCAAAAGTTACAAGGAAGTTCAGTTA   60   
Chr13 X-MLV     TTGCAAGGCATGAAAAAGTACCAGAGCTGAGTTCTCAAAAGTTACAAGGAAGTTCAGTTA  
                ************ ***************************************** * *** 
 
XMRV            AAGAATAA--------------GGCTGAATAACACTGGGACAGGGGCCAAACAGGATATC 7880 
EKVX            AAGATTAACAGTTACAAATCAAGGCTGAATAATACTAGGACAAGGGCCAAACAGGATATC  120 
Chr13 X-MLV     AAGATTAACAGTTAAAAATCAAGGCTGAATAATACTAGGACAAGGGCCAAACAGAATATC  
                **** ***              ********** *** ***** *********** ***** 
 
XMRV            TGTAGTCAGGCACCTGGGCCCCGGCTCAGGGCCAAGAACAGATGGTCCTCAGATAAAGCG 7940 
EKVX            GGTGGTCAAGCGCCTGGGCCCCGGCTCAGGGCCAAGAACAGATGGTACCCAGATAAAGCG  180 
Chr13 X-MLV     GGTGGTCAAGCGCCTGGGCCCCGGCTCAGGGCCAAGAACAGATGGTACCCAGATAAAGCG  
                 ** **** ** ********************************** * *********** 
 
XMRV            AAACTAACAACAGTTTCTGGAAA-GTCCCACCTCAGTTTCAAGTTCCCCAAAAGACCGGG 7999 
EKVX            GAACCAGCAACAGTTTCTGAAAAAGTCCCACCTCAGTTTCAGGTTCCCCAAATGACCAGG  240 
Chr13 X-MLV     GAACCAGCAACAGTTTCTGAAAAAGTCCCACCTCAGTTTCAGGTTCCCCAAATGACCAGG  
                 *** * ************ *** ***************** ********** **** ** 
 
XMRV            AAATACCCCAAGCCTT-ATTTAAACTAACCAATCAGCTCGCTTCTCGCTTCTGTACCCGC 8058 
EKVX            AAATACCCCAAGCCTTGATTTGAACTAACCACTCAGCTCGCTTCTCGCTTCTGTACCCGC  300 
Chr13 X-MLV     AAATACCCCAAGCCTTGATTTGAACTAACCACTCAGCTCGCTTCTCGCTTCTGTACCCAC  
                **************** **** ********* ************************** * 
 
XMRV            GCTTTTTGCTCCCCAGTCCTAGCCCTATAAAAAAGGGGTAAGAACTCCACACTCGGCGCG    3 
EKVX            GCTTTTTGCTCCCCAGCCCCAGCCCTATAAAAA--GGGTAAGAACTCCACACTCGGCGCG  358 
Chr13 X-MLV     GCTTTTTGCTCCCCAGCCCCAGCCCTATAAAAA--GGGTAAGAACTCCACACTCGGCGCG  
                **************** ** *************  ************************* 
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XMRV            CCAGTCATCCGATAGACTGAGTCGCCCGGGTACCCGTGTTCCCAATAAAGCCTTTTGCTG   63 
EKVX            CCAGTCCTCCGACAGACTGAGTCGCCCGGGTACCCGTGTTCCCAATAAAGCCTCTTGCTG  418 
Chr13 X-MLV     CCAGTCCTCCGATAGACTGAGTCGCCCGGGTACCCGTGTTCCCAATAAAGCCTCTTGCTG  
                ****** ***** **************************************** ****** 
 
XMRV            TTTGCATCCGAAGCGTGGCCTCGCTGTTCCTTGGGAGGGTCTCCTCAGAGTGATTGACTA  123 
EKVX            ATTACATCCGAATCGTGGTCTCGCTGATCCTTGGGAGGGTCTCCTCAGATT----GACCA  474 
Chr13 X-MLV     ATTACATCCGAATCGTGGTCTCGCTGATCCTTGGGAGGGTCTCCTCAGATTGATTGACCA  
                 ** ******** ***** ******* ********************** *    *** * 
 
XMRV            CCCAGCTCGGGGGTCTTTCATTTGGGGGCTCGTCCGGGATTCGGAGACCCCCGCCCAGGG  183 
EKVX            CCCACCTCGGGGGTCTTTCATTTGGAGGTTCCACCGAGATTAGGAGACCCCTGCCCAGGG  534 
Chr13 X-MLV     CCCACCTCGGGGGTCTTTCATTTGGAGGTCCCACCGAGATTAGGAGACCCCTGCCCAGGG  
                **** ******************** **  *  *** **** ********* ******** 
 
XMRV            ACCACCGACCCACCGTCGGGAGGTAAGCCGGCCGGCGATCGTTTTGTCTTTGTCTCTGTC  243 
EKVX            ACCACCGACCC-CCGCCGGGAGGTAAGCTGGCCAGCGGTCGTTTCGTGTCTGTCTCTGTC  593 
Chr13 X-MLV     ACCACCGACCC-CCGCCGGGAGGTAAGCTGGCCAGCGGTCGTTTCGTGTCTGTCTCTGTC  
                *********** *** ************ **** *** ****** ** * ********** 
 
XMRV            TTTGTGCGTGTGTGTGTGTGCCGGCATCTAATCCTCGCGCCTGCGTCTGAATCTGTACTA  303 
EKVX            TCCGTGCGTGTCTGTG----CCGGCATCTAATGTTTGCGCCTGCGTCTG------TACTA  643 
Chr13 X-MLV     TCCGTGCGTGTCTGTG----CCGGCATCTAATGTTTGCGCCTGCGTCTG------TACTA  
                *  ******** ****    ************  * *************      ***** 
 
XMRV            GTTAGCTAACTAGATCTGTATCTGGCGGTTCCGCGGAAGAACTGACGAGTTCGTATTCCC  363 
EKVX            GTTGGCTAACTAGATCTGAATCTGGCGGTTCCGTGGAAGAACTGACGAGTTCATATTCCC  703 
Chr13 X-MLV     GTTGGCTAACTAGATCTGAATCTGGCGGTTCCGTGGAAGAACTGACGAGTTCATATTCCC  
                *** ************** ************** ****************** ******* 
 
XMRV            GGCCGCAGCCCTGGGAGACGTCCCAGCGGCCTCGGGGGCCCGTTTTGTGGCCCATTCTGT  423 
EKVX            GGCCGCAGCCCTGGGAGACGTCTCAGAGGCATCGGGGGCCATCTTTGTGGCCCAATCTGT  763 
Chr13 X-MLV     GGCCGCAGCCCTGGGAGACGTCTCAGAGGCATCGGGGGCCATCTTTGTGGCCCAATCTGT  
                ********************** *** *** *********   *********** ***** 
 
XMRV            ATCAGTTAACCT-ACCCGAGTCGGACTTTTTGGAG------------------------T  458 
EKVX            ATCTGAGAACCCGACCCGTCTCGGACTCTTTGGAGCCTCTCCTTTGACCGAGGGATACGT  823 
Chr13 X-MLV     ATCTGAGAACCCGACCCGTCTCGGACTCTTTGGAGCCTCTCCTTTGACCGAGGGATACGT  
                *** *  ****  *****  ******* *******                        * 
 
XMRV            GGCTTTGTTGGGGGACGAGAGACAGAGACACTTCCCGCCCCCGTCTGAATTTTTGCTTTC  518 
EKVX            GGTTCTGTTGGGCGGCGAGGGGCCGAAACGCTCCTCTCCCCCATCTGAATTTTTGCTTTC  883 
Chr13 X-MLV     GGTTCTGTTGGGCGGCGAGGGGCCGAAACGCTCCCCTCCCCCATCTGAATTTTTGCTTTC  
                ** * ******* * **** * * ** ** ** * * ***** ***************** 
 
XMRV            GGTTTTACGCCGAAACCGCGCCGCGCGTCTGATTTGTTTTGTTGTTCTTCTGTTCTTCGT  578 
EKVX            GGTTTTCCGCCGAAACCGCGCCGCGCGTCTTGTCTGTCTCTGTGTTGTTTTGTCATTTGT  943 
Chr13 X-MLV     GGTTTTCCGCCGAAACCGCGCCGCGCGTCTTGTCTGTCTCTGTGTTGTTTTGTCATTTGT  
                ****** ***********************  * *** *   **** ** ***  ** ** 
 
XMRV            TAGTTTTCTTCTGTCTTTAAGTGTTCTCGAGATCATGGGACAGACCGT  626 
EKVX            CGGTTCGTTATTGTTTTGGACCGTTTCTAAAAATATGGGACAGACCGT  991 
Chr13 X-MLV     CGGTTCGTTATTGTTTTGGACCGTTTCTAAAAATATGGGACAGACCGT  
                  ***   *  *** **  *  ***    * *  ************** 
 
B 
 
XMRV            CTATATTTTGACTTGTGTGATTTAGTTGGAGACAACTGGGATGACCCGGAACCCGATATT 6029 
EKVX            CTATATTTTGACCTGTGTGATTTAGTAGGAGACTACTGGGATGACCCAGAACCCGATATT   60 
Chr13 X-MLV     CTATATTTTGACCTGTGTGATTTAGTAGGAGACTACTGGGATGACCCAGAACCCGATATT  
                ************ ************* ****** ************* ************ 
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XMRV            GGAGATGGTTGCCGCTCTCCCGGGGGAAGAAAAAGGACAAGACTATATGATTTCTATGTT 6089 
EKVX            GGGGATGGTTGCCGCACTCCCGGGGGAAGAAGAAGGACAAGACTGTATGACTTCTATGTT  120   
Chr13 X-MLV     GGGGATGGTTGCCGCACTCCCGGGGGAAGAAGAAGGACAAGACTGTATGACTTCTATGTT  
                ** ************ *************** ************ ***** ********* 
 
XMRV            TGCCCCGGTCATACTGTATTAACAGGGTGTGGAGGGCCGAGAGAGGGCTACTGTGGCAAA 6149 
EKVX            TGCCCCGGTCATACTGTACCAATAGGGTGTGGAGGGCCGGGAGAGGGCTACTGTGGCAAA  180 
Chr13 X-MLV     TGCCCCGGTCATACTGTACCAATAGGGTGTGGAGGGCCGGGAGAGGGCTACTGTGGCAAA  
                ******************  ** **************** ******************** 
 
XMRV            TGGGGATGTGAGACCACTGGACAGGCATACTGGAAGCCATCATCATCATGGGACCTAATT 6209 
EKVX            TGGGGATGTGAGACCACTGGACAGGCATACTGGAAGCCATCATCATCATGGGACCTAATT  240 
Chr13 X-MLV     TGGGGATGTGAGACCACTGGACAGGCATACTGGAAGCCATCATCATCATGGGACCTAATT  
                ************************************************************ 
 
XMRV            TCCCTTAAGCGAGGAAACACTCCTAAGGGTCAGGGCCCCTGTTTTGATTCCTCAGTGGGC 6269 
EKVX            TCCCTTAAGCGAGGAAACACTCCTAAGGATCAGGGCCCCTGTTWTGATTCCTCGGT---C  297 
Chr13 X-MLV     TCCCTTAAGCGAGGAAACACTCCTAAGGATCAGGGCCCCTGTTATGATTCCTCGGT---C  
                **************************** ************** ********* **   * 
 
XMRV            TCCGGTAGCATCCAGGGTGCCACACCGGGGGGTCGATGCAACCCCCTAGTCCTAGAATTC 6329 
EKVX            TCCAGTGGCGTCCAGGGTGCCACACCGGGGGGTCGATGCAACCCCCTGGTCTTAGAATTC  357 
Chr13 X-MLV     TCCAGTGGCGTCCAGGGTGCCACACCGGGGGGTCGATGCAACCCCCTGGTCTTAGAATTC  
                *** ** ** ************************************* *** ******** 
 
XMRV            ACTGACGCGGGTAAAAGGGCCAGCTGGGATGCCCCCAAAACATGGGGACTAAGACTGTAT 6389 
EKVX            ACTGACTCGGGTAGAAAGGCCAGCTGGGATGCCCCCAAAGTTTGGGGACTAAGACTCTAT  417 
Chr13 X-MLV     ACTGACGCGGGTAGAAAGGCCAGCTGGGATGCCCCCAAAGTTTGGGGACTAAGACTCTAT  
                ****** ****** ** **********************   ************** *** 
 
XMRV            CGATCCACTGGGGCCGACCCGGTGACCCTGTTCTCTCTGACCCG 6433 
EKVX            CGATCCACAGGGGCCGACCCGGTGACCCGGTTCTCTTTGACCCG  461 
Chr13 X-MLV     CGATCCACAGGGGCCGACCCGGTGACCCGGTTCTCTTTGACCCG  
                ******** ******************* ******* ******* 
 
C 
 
XMRV            GCCCTGGTTCTGACCCAACAGTATCACCAACTCAAATCAATAGATCCAGAAGAAGTGGAA 7679 
EKVX            GCCCTGGTCCTGACCCAACAGTATCACCAACTCAAATCAATAGATCCAGAAGCAGTGGAA   60 
Chr13 X-MLV     GCCCTGGTCCTGACCCAACAGTATCACCAACTCAAATCAATAGATCCAGAAGCAGTGGAA  
                ******** ******************************************* ******* 
 
XMRV            TCACGTGAATAAAAGATTTTATTCAGTTTCCAGAAAGAGGGGGGAATGAAAGACCCCACC 7739 
EKVX            ACACGTGAATAAAAGATTTTATTCAGTTTCCAGAAAGAGGGGGGAATGAAAGACCCCACC  120    
Chr13 X-MLV     ACACGTGAATAAAAGATTTTATTCAGTTTCCAGAAAGAGGGGGGAATGAAAGACCCCACC  
                 *********************************************************** 
 
XMRV            ATAAGGCTTAGCACGCTAGCTACAGTAACGCCATTTTGCAAGGCATGGAAAAGTACCAGA 7799 
EKVX            ATAAGGCTTAGCAAGCTAGCTGCAGTAACGCCATTTTGCAAGGCATGAAAAAGTACCAGA  180 
Chr13 X-MLV     ATAAGGCTTAGCAAGCTAGCTGCAGTAACGCCATTTTGCAAGGCATGAAAAAGTACCAGA  
                ************* ******* ************************* ************ 
 
XMRV            GCTGAGTTCTCAAAAGTTACAAGGAAGTTTAATTAAAGAATAA--------------GGC 7845 
EKVX            GCTGAGTTCTCAAAAGTTACAAGGAAGTTCAGTTAAAGATTAACAGTTACAAATCAAGGC  240 
Chr13 X-MLV     GCTGAGTTCTCAAAAGTTACAAGGAAGTTCAGTTAAAGATTAACAGTTAAAAATCAAGGC  
                ***************************** * ******* ***              *** 
 
XMRV            TGAATAACACTGGGACAGGGGCCAAACAGGATATCTGTAGTCAGGCACCTGGGCCCCGGC 7905 
EKVX            TGAATAATACTAGGACAAGGGCCAAACAGGATATCGGTGGTCAAGCGCCTGGGCCCCGGC  300 
Chr13 X-MLV     TGAATAATACTAGGACAAGGGCCAAACAGAATATCGGTGGTCAAGCGCCTGGGCCCCGGC  
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XMRV            TCAGGGCCAAGAACAGATGG 7925 
EKVX            TCAGGGCCAAGAACAGATGG 320 
Chr13 X-MLV     TCAGGGCCAAGAACAGATGG  
                ******************** 
Our results confirm the findings of Sfanos et al. [92], who published the results of a similar study 
while this manuscript was in preparation for publication. They tested 58 of the 60 cell lines of the NCI-
60 panel, and like us, found EKVX to be the only one of these cell lines expressing an X-MLV. An 
important difference between their study and ours is that the cell lines tested by Sfanos et al. were 
obtained from the NCI and then cultured in their own laboratory, whereas our initial screen was 
conducted on materials (DNA and cell pellets) directly supplied by the DTP, providing an additional 
level of confidence that the virus is present in the source cell line maintained by the DTP. Additionally, 
we utilized a different envelope antibody and different PCR primers, further strengthening the validity 
of the findings of both papers. 
3. Experimental Section  
3.1. Cell Line Materials and Cell Culture  
Frozen cell pellets and genomic DNA were obtained from the DTP. EKVX cells were obtained 
from the DTP, and LNCaP cells were obtained from the laboratory of F. Ruscetti, NCI. Both cell lines 
were cultured in RPMI supplemented with penicillin/streptomycin and 10% fetal bovine serum.  
3.2. Immunoblotting  
Total protein lysates were prepared as previously described [93], and 30 g were subjected to 
electrophoresis on 4-12% Bis-Tris gels (Invitrogen, Carlsbad, CA) with MOPS buffer and transferred 
to nitrocellulose. Monoclonal antibody 7C10 [61], polyclonal goat antisera against Rauscher MLV p30 
(NCI, Bethesda, MD), and -actin antibody (Novus Biologicals, Littleton, CO) were used as primary 
antibodies. Detection was accomplished with horseradish peroxidase-labeled secondary antibodies and 
enhanced chemiluminescent substrate (Thermo Scientific, Rockford, IL). XMRV-infected LNCaP cell 
lysate, provided by F. Ruscetti, was used as a positive control.  
3.3. PCR  
PCR for XMRV gag sequences was carried out on 75 ng of genomic DNA in a 25 l reaction using 
primers 419F and 1154R and conditions as previously described [94] except the final concentration of 
each primer was 0.2 M and the extension step was shortened to 45 s. PCR for XMRV env sequences 
was carried out similarly with primers 5922F (5-GCTAATGCTACCTCCCTCCTGG) and 6454R (5-
GGCCCTACATTGAGGACCTGG) with an annealing temperature of 58C. Hot-StartIt FideliTaq 
(USB, Cleveland, OH) was used for PCR. No template (water) controls and an XMRV-infected 
positive control (provided by F. Ruscetti) were included. In some cases, 150 ng genomic DNA was 
spiked with 1.5 pg or 0.15 pg (0.15 pg/150 ng approximates 1 provirus copy per cell) plasmid DNA 
containing the XMRV env sequence (provided by F. Ruscetti). Nested PCR was carried out on 1.5 µl 
of the first round product in a 25 l reaction as previously described for gag [94] and at an annealing Viruses 2011, 3                                       
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temperature of 58°C using primers 5942F (5-GGGGACGATGACAGACACTTTCC) and 6271R (5-
GAGCCCACTGAGGAATCAAAACAG) for env. PCR products were analyzed by electrophoresis on 
1.5-2% agarose gels and staining with ethidium bromide.  
Nested PCR was carried out as described [62] to test for the presence of mouse mitochondrial DNA 
in 250 ng EKVX genomic DNA. Single-round PCR for intracisternal A particles (IAP) for 45 cycles 
on up to 600 ng of EKVX genomic DNA was carried out as published  [63].  
Additional PCR products were generated for sequencing using Finnzyme Phusion polymerase (New 
England Biolabs, Ipswich, MA) with up to 200 ng genomic DNA in 100 µl reactions containing the 
HF buffer supplied by the manufacturer, 200 M dNTPs, and 0.5 M each primer. Primers were 
designed to amplify regions in the LTR, gag, and env based on the sequence of DG-75 X-MLV 
(GenBank accession no. AF221065). Primers and conditions used were: DG-75 7762F (5-
CAAGCTAGCTGCAGTAACGCCATT) and DG-75 287R (5-
CAGACGCAGGCGCAAACATTAGAT) with initial denaturation for 30 s at 98°C followed by 35 
cycles of denaturation at 98°C for 8 s and annealing/extension at 72°C for 15 s, followed by a final 
extension at 72°C for 7 min; DG-75 7607F (5-AAAGGCAGAATTTCGGTGGTGCAG) and DG-75 
7968R (5-TGCTGGTTCCGCTTTATCTGGGTA) with the same conditions; and DG-75 7945R (5-
TACCCAGATAAAGCGGAACCAGCA) and DG-75 664R (5-
AGGGTCAGACTCAAAGGAGTGGTT) with initial denaturation for 30 s at 98°C followed by 35 
cycles of denaturation at 98°C for 8 s, annealing at 70°C for 20 s, and extension at 72°C for 26 s, 
followed by a final extension at 72°C for 7 min. Products were separated on 2% agarose gels and 
extracted using a QiaexII Gel Extraction Kit (Qiagen, Valencia, CA).  
3.4. Sequencing and Alignment  
Sanger sequencing was performed by the Laboratory of Molecular Technology, SAIC-Frederick. 
Sequences were assembled using Geneious v5.1.6 [95]. Sequences were aligned with representative 
XMRV and X-MLV sequences using Clustal W2 (www.ebi.ac.uk/Tools/msa/clustalw2) [96,97]. 
Sequences have been deposited with GenBank with accession numbers JN861040, JN861041, and 
JN861042.  
3.5. Cell-free Virus Transmission Assay  
Supernatants were collected from cultures of EKVX cells 24 hours after a media change and were 
passed through 0.45 m filters. For virus infection, subconfluent LNCaP cells in 6-well dishes were 
pretreated with polybrene (4 g/ml), then the media was removed and replaced with cell-free EKVX 
supernatant or fresh media (negative control) containing polybrene (2 g/ml). After 5 hours incubation, 
the media was changed in each well. Cells were subcultured and total protein lysates were prepared at 
10 and 16 days post-infection. Analysis for viral proteins by immunoblotting was carried out.  
4. Conclusions  
The human lung adenocarcinoma cell line EKVX produces an X-MLV that is infectious to human 
cells. Because the EKVX cell line was established following the passage of the original tumor cells in Viruses 2011, 3                                       
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nude mice, the source of the virus may be the activation of an endogenous virus in the mouse rather 
than the original human tumor. Regardless of the origin of the X-MLV in the cell line EKVX, its 
discovery serves as a reminder to handle all human-derived cell lines, even those tested for known 
human pathogens, with caution.  
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